Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

“GLP-1 helped me enhance everything that I was already doing — eating healthy and working out,” the tennis champion tells PEOPLE Serena Williams reveals to PEOPLE that she’s been using a GLP-1 ...

Share on Pinterest An increasing number of people without diabetes are using GLP-1 agonist drugs for weight loss only. Image credit: MarkHatfield/Getty Images. The last few years have seen a marked ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...